226 related articles for article (PubMed ID: 34868337)
21. Detection of subtype-specific breast cancer surface protein biomarkers via a novel transcriptomics approach.
Mercatelli D; Formaggio F; Caprini M; Holding A; Giorgi FM
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34750607
[TBL] [Abstract][Full Text] [Related]
22. Molecular pathogenesis of breast cancer: impact of miR-99a-5p and miR-99a-3p regulation on oncogenic genes.
Shinden Y; Hirashima T; Nohata N; Toda H; Okada R; Asai S; Tanaka T; Hozaka Y; Ohtsuka T; Kijima Y; Seki N
J Hum Genet; 2021 May; 66(5):519-534. PubMed ID: 33177704
[TBL] [Abstract][Full Text] [Related]
23. Identification and characterization of three Siglec15-related immune and prognostic subtypes of breast-invasive cancer.
Cao X; Zhou Y; Mao F; Lin Y; Zhou X; Sun Q
Int Immunopharmacol; 2022 May; 106():108561. PubMed ID: 35151947
[TBL] [Abstract][Full Text] [Related]
24. [High expression of MRPL13 promotes cell cycle progression and proliferation of gastric cancer cells by inhibiting p53 signaling to affect long-term prognosis].
Wang L; Xia Y; Zhang Z; Liu X; Shi J; Wang Y; Li J; Zhnag X; Geng Z; Song X; Zuo L
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Sep; 43(9):1558-1566. PubMed ID: 37814870
[TBL] [Abstract][Full Text] [Related]
25. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H
BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748
[TBL] [Abstract][Full Text] [Related]
26. Characterization of alternative splicing events and prognostic signatures in breast cancer.
Han P; Zhu J; Feng G; Wang Z; Ding Y
BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
[TBL] [Abstract][Full Text] [Related]
27. A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer.
Liu Z; Mi M; Li X; Zheng X; Wu G; Zhang L
J Cell Mol Med; 2020 Nov; 24(21):12444-12456. PubMed ID: 32967061
[TBL] [Abstract][Full Text] [Related]
28. In silico screening using bulk and single-cell RNA-seq data identifies RIMS2 as a prognostic marker in basal-like breast cancer: A retrospective study.
Zhang L; Liu Z; Zhu J
Medicine (Baltimore); 2021 Apr; 100(16):e25414. PubMed ID: 33879671
[TBL] [Abstract][Full Text] [Related]
29. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
30. MRPL13 is a Prognostic Cancer Biomarker and Correlates with Immune Infiltrates in Breast Cancer.
Tao Z; Suo H; Zhang L; Jin Z; Wang Z; Wang D; Wu M; Peng N; Zhao Y; Chen B
Onco Targets Ther; 2020; 13():12255-12268. PubMed ID: 33273831
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of the value of RAB family genes in prognosis of breast invasive carcinoma.
Lin S; Cao C; Meng Y; Wu P; Gao P; Zhi W; Peng T; Wu P; Gui L
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32432324
[TBL] [Abstract][Full Text] [Related]
32. Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients.
Maciejczyk A; Łacko A; Ekiert M; Jagoda E; Wysocka T; Matkowski R; Hałoń A; Györffy B; Lage H; Surowiak P
Histol Histopathol; 2013 Apr; 28(4):513-24. PubMed ID: 23364898
[TBL] [Abstract][Full Text] [Related]
33. Bromodomain 4 is a potent prognostic marker associated with immune cell infiltration in breast cancer.
Zhong L; Yang Z; Lei D; Li L; Song S; Cao D; Liu Y
Basic Clin Pharmacol Toxicol; 2021 Jan; 128(1):169-182. PubMed ID: 32799413
[TBL] [Abstract][Full Text] [Related]
34. Expression Pattern and Prognostic Value of EPHA/EFNA in Breast Cancer by Bioinformatics Analysis: Revealing Its Importance in Chemotherapy.
Liang Z; Wang X; Dong K; Li X; Qin C; Zhou H
Biomed Res Int; 2021; 2021():5575704. PubMed ID: 33977106
[TBL] [Abstract][Full Text] [Related]
35. GNPNAT1 is a potential biomarker correlated with immune infiltration and immunotherapy outcome in breast cancer.
Yuan R; Zhang Y; Wang Y; Chen H; Zhang R; Hu Z; Chai C; Chen T
Front Immunol; 2023; 14():1152678. PubMed ID: 37215111
[TBL] [Abstract][Full Text] [Related]
36. Lactate-mediated mitoribosomal defects impair mitochondrial oxidative phosphorylation and promote hepatoma cell invasiveness.
Lee YK; Lim JJ; Jeoun UW; Min S; Lee EB; Kwon SM; Lee C; Yoon G
J Biol Chem; 2017 Dec; 292(49):20208-20217. PubMed ID: 28978646
[TBL] [Abstract][Full Text] [Related]
37. EIF4G1 Is a Potential Prognostic Biomarker of Breast Cancer.
Li K; Tan G; Zhang X; Lu W; Ren J; Si Y; Adu-Gyamfi EA; Li F; Wang Y; Xie B; Wang M
Biomolecules; 2022 Nov; 12(12):. PubMed ID: 36551184
[TBL] [Abstract][Full Text] [Related]
38. Prognostic biomarkers related to breast cancer recurrence identified based on Logit model analysis.
Zhou X; Xiao C; Han T; Qiu S; Wang M; Chu J; Sun W; Li L; Lin L
World J Surg Oncol; 2020 Sep; 18(1):254. PubMed ID: 32977823
[TBL] [Abstract][Full Text] [Related]
39. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value and immunological role of PDCD1 gene in pan-cancer.
Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D
Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
